About FSHD Facioscapulohumeral
muscular dystrophy (FSHD) refers to a rare genetic myopathy affecting approximately 19,000 people in the U.
During an oral presentation yesterday afternoon, Quest Diagnostics' investigators presented results of a study that found that molecular combing identified certain genomic characteristics that indicate facioscapulohumeral
dystrophy (FSHD), the third most common muscular dystrophy.
Other, less severe forms of muscular dystrophy include Becker muscular dystrophy (BMD), Emery-Dreifuss muscular dystrophy (EDMD), facioscapulohumeral
muscular dystrophy (FMD), limb-girdle muscular dystrophy (LGMD) and myotonic dystrophy (MMD).
Resolaris(TM) is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral
muscular dystrophy (FSHD).
muscular dystrophy, or FSHD, is the world's third most common type of muscular dystrophy.
edu/crc/Fabry 1,2,3,7,9 FACIAL DISFIGUREMENT See: Craniofacial Disorders FACIAL PARALYSIS See: Bell's Palsy FACIO-AURICULO-VERTEBRAL ANOMALY See: Goldenhar Syndrome FACIO-CARDIO-CUTANEOUS SYNDROME See: Cardio-Facio-Cutaneous Syndrome FACIOGENITAL SYNDROME See: Aarskog Syndrome FACIOSCAPULOHUMERAL
MUSCULAR DYSTROPHY FSH Society, Inc.
Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that the first patient has been dosed in a newly initiated long term-safety extension study of Resolaris(TM) for adult patients with facioscapulohumeral
muscular dystrophy (FSHD), a rare and severe genetic myopathy for which there are currently no approved treatments.
Exploring a new target for facioscapulohumeral
muscular dystrophy (FSHD): Stanford University scientists in Palo Alto, Calif.
Resolaris(TM) Franchise Expansion on Track for Planned Initiation of Phase 1b/2 Trials in Early Onset Facioscapulohumeral
Muscular Dystrophy and Limb-Girdle Muscular Dystrophy
Our ongoing Phase 1b/2 clinical trial is continuing on track in facioscapulohumeral
muscular dystrophy (FSHD) as the first orphan indication for Resolaris(TM), our natural immuno-modulator and lead product candidate, thanks to the leadership and expertise of David, Kelly and Melissa," said John Mendlein, Ph.
Update on its Lead Candidate Resolaris(TM)-- The Company noted that its lead candidate, Resolaris(TM), is undergoing a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral
muscular dystrophy (FSHD).
SHIFT Communications, an award winning agency, most recently received a Gold Bell from the Publicity Club of New England for their work with the FSH Society's "Selfies for a Cause" campaign -- an integrated communications campaign aimed at driving awareness and education related to the disease, facioscapulohumeral